(Q38095862)

28 August 2017

title

Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy (English)

1 reference

systemic lupus erythematosus

28 August 2017

1 reference

1 reference

1 reference

J Mosak

1

1 reference

28 August 2017

R Furie

series ordinal

2

1 reference

28 August 2017

publication date

1 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

22

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

361-371

1 reference

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312471575

21 January 2018

Identifiers

DOI

10.1177/0961203312471575

1 reference

28 August 2017

1 reference